SIGA Technologies

SIGA Technologies, Inc.
Company typePublic
Nasdaq: SIGA
Russell 2000 Component
IndustryHealthcare
Biotechnology
Health security
FoundedDecember 28, 1995; 28 years ago (1995-12-28)[1]
Headquarters
New York City
,
United States
Key people
Diem Nguyen, Ph.D. (CEO)
Dennis E. Hruby, Ph.D. (CSO)
ProductsPharmaceutical agents
RevenueIncrease $133.7 million (2021)
Increase $89.1 million (2021)
Increase $69.5 million (2021)
Number of employees
39 (2022)
Websitesiga.com
Footnotes / references
[2]

SIGA Technologies, Inc. is an American pharmaceutical company founded in 1995, based in New York City, which develops and sells pharmaceutical solutions for the antiviral treatment of smallpox, monkeypox, cowpox, and vaccinia complications.[3][4][5][6]

  1. ^ "SIGA Technologies Inc". Reuters. Retrieved April 30, 2019.
  2. ^ "SIGA Technologies, Inc. FORM 10-K". U.S. Securities and Exchange Commission. Retrieved May 23, 2022.
  3. ^ "Company Business Summary".
  4. ^ "Monkeypox outbreak: Drugmaker SIGA says EU authorities seeking to stockpile its smallpox antiviral". Euronews Next. May 20, 2022. Retrieved May 24, 2022.
  5. ^ "SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat". SIGA Technologies. Retrieved May 24, 2022.
  6. ^ "Summary Of Product Characteristics" (PDF). European Medicines Agency. Retrieved May 24, 2022.